Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

February 10, 2021

Study Completion Date

December 31, 2025

Conditions
Relapsed Angioimmunoblastic T-Cell LymphomaRefractory Angioimmunoblastic T-cell Lymphoma
Interventions
DRUG

Oral azacitidine

Azacitidine tablets

DRUG

Romidepsin

Romidepsin injection

DRUG

Bendamustine

Bendamustine injection

DRUG

Gemcitabine

Gemcitabine injection

Trial Locations (27)

Unknown

University Hospital for Internal Medicine - University Hospital Graz, Graz

Medical University of Vienna, Vienna

A. Z. Sint-Jan Brugge-Oostende AV, Bruges

Cliniques Universitaires de Bruxelles - Hôpital Erasme, Brussels

CHU UCL Namur - Site Godinne, Yvoir

Aarhus University Hospital, Aarhus

Institut d'Hématologie de Basse Normandie, Caen

CHU de Clermont-Ferrand - Hôpital Estaing, Clermont-Ferrand

CHU Henri Mondor, Créteil

CHU de Dijon, Dijon

CHU de Grenoble, Grenoble

CHRU de Lille, Lille

CHU de Montpellier - Hôpital Saint-Eloi, Montpellier

CHU de Nantes - Hôtel Dieu, Nantes

Hôpital Necker, Paris

Hôpital Saint-Louis, Paris

CHU Haut-Lévèque - Centre François Magendie, Pessac

CHU Lyon-Sud, Pierre-Bénite

CH Annecy Genevois, Pringy

CHU Pontchaillou, Rennes

Centre Henri Becquerel, Rouen

IUCT - Oncopole, Toulouse

CHRU de Nancy - Hôpital de Brabois, Vandœuvre-lès-Nancy

University College London Hospital, London

The Christie, Manchester

Nottingham City Hospital, Nottingham

Churchill Hospital, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

The Lymphoma Academic Research Organisation

OTHER